

G1 H,Ak

G2 Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,O,N

Structure attributes must be viewed using STN Express query preparation.

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> s l2 sss full
FULL SEARCH INITIATED 13:25:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  53916 TO ITERATE

100.0% PROCESSED   53916 ITERATIONS                                881 ANSWERS
SEARCH TIME: 00.00.01

L4          881 SEA SSS FUL L2

=> s l3 sss full
FULL SEARCH INITIATED 13:25:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 249729 TO ITERATE

100.0% PROCESSED  249729 ITERATIONS                              56190 ANSWERS
SEARCH TIME: 00.00.05

L5        56190 SEA SSS FUL L3

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY     SESSION
FULL ESTIMATED COST                              315.04      315.25

FILE 'CAPLUS' ENTERED AT 13:26:15 ON 11 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 11 Mar 2004  VOL 140 ISS 11
FILE LAST UPDATED: 10 Mar 2004  (20040310/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l4 and T cell proliferation
          646 L4
       712550 T
      1751206 CELL
      1560362 CELLS
      2348973 CELL
                (CELL OR CELLS)
       154488 PROLIFERATION
          725 PROLIFERATIONS
       154947 PROLIFERATION
                (PROLIFERATION OR PROLIFERATIONS)
         5682 T CELL PROLIFERATION
                (T(W)CELL(W)PROLIFERATION)
```

```
L6            1 L4 AND T CELL PROLIFERATION

=> s l5 and T cell proliferation
         21560 L5
        712550 T
       1751206 CELL
       1560362 CELLS
       2348973 CELL
                 (CELL OR CELLS)
        154488 PROLIFERATION
           725 PROLIFERATIONS
        154947 PROLIFERATION
                 (PROLIFERATION OR PROLIFERATIONS)
          5682 T CELL PROLIFERATION
                 (T(W)CELL(W)PROLIFERATION)
L7            5 L5 AND T CELL PROLIFERATION

=> d l6 ibib abs hitstr

L6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2000:824108  CAPLUS
DOCUMENT NUMBER:          134:536
TITLE:                    Chemical compounds having potassium channel blocking
                          activity for the treatment of immune dysfunction
INVENTOR(S):              Jensen, Bo Skaaning; Olesen, Soren Peter;
                          Christophersen, Palle
PATENT ASSIGNEE(S):       Neurosearch A/S, Den.
SOURCE:                   PCT Int. Appl., 45 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ----------------  ----  --------       ---------------  --------
     WO 2000069439      A1   20001123       WO 2000-DK253    20000512
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1181016         A1   20020227       EP 2000-926719   20000512
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     US 2002065247      A1   20020530       US 2001-986725   20011109
PRIORITY APPLN. INFO.:                   DK 1999-659      A  19990512
                                         WO 2000-DK253    W  20000512

OTHER SOURCE(S):          MARPAT 134:536
AB   The present invention relates to chemical compds. having inhibitory activity
     on an intermediate conductance Ca2+-activated potassium channel (IKCa) in
     T- and B-lymphocytes, and the use of such compds. for the treatment or
     alleviation of diseases or conditions related to immune dysfunction.  The
     invention also provides a pharmaceutical compns. comprising an effective
     amount of a IKCa blocker for treatment or alleviation of diseases or
     conditions related to immune dysfunction.  For example, T
```

cell proliferation was assays 6 days after cells were stimulated in culture with antigen in the presence of cyclosporin A, or cyclosporin A and clotrimazole, resp. Clotrimazole (10 μM) was added 30 min prior to the addition of antigen. The cyclosporin A-mediated inhibition of **T cell proliferation** is shifted leftwards by 10 μM clotrimazole, from a 50% inhibition of proliferation at approx. 25 nM cyclosporin A to half-maximal inhibition at 2.5 nM cyclosporin A.

IT **795-36-8**, 1,1,1-Triphenylacetone **197526-28-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing potassium channel blockers and immunosuppressants for treatment of immune dysfunction)

RN 795-36-8 CAPLUS
CN 2-Propanone, 1,1,1-triphenyl- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 197526-28-6 CAPLUS
CN 1-Piperidineacetic acid, α,α-diphenyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l7 1-5 ibib abs hitstr

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:482091 CAPLUS
DOCUMENT NUMBER: 139:180287
TITLE: Exploring Structure-Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase
AUTHOR(S): Evans, Gary B.; Furneaux, Richard H.; Lewandowicz, Andrzej; Schramm, Vern L.; Tyler, Peter C.
CORPORATE SOURCE: Carbohydrate Chemistry, Industrial Research Limited, Lower Hutt, N. Z.
SOURCE: Journal of Medicinal Chemistry (2003), 46(15), 3412-3423
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:180287
AB The aza-C-nucleosides, Immucillin-H and Immucillin-G, are transition state

analog inhibitors of purine nucleoside phosphorylase, a therapeutic target for the control of **T-cell proliferation**.
Immucillin analogs modified at the 2'-, 3'-, or 5'-positions of the aza sugar moiety or at the 6-, 7-, or 8-positions of the deazapurine, as well as methylene-bridged analogs, have been synthesized and tested for their inhibition of human purine nucleoside phosphorylase. All analogs were poorer inhibitors, which reflects the superior capture of transition state features in the parent immucillins.

IT **402477-42-3P 402477-45-6P 577978-29-1P 577978-30-4P 577978-31-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(exploring structure activity relationships of transition state analogs of human purine nucleoside phosphorylase)

RN 402477-42-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3,4-dihydroxy-2-[4-methoxy-5-[(phenylmethoxy)methyl]-5H-pyrrolo[3,2-d]pyrimidin-7-yl]-5-[(triphenylmethoxy)methyl]-, 1,1-dimethylethyl ester, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402477-45-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4-[(4-methoxyphenyl)methoxy]-5-[4-methoxy-5-[(phenylmethoxy)methyl]-5H-pyrrolo[3,2-d]pyrimidin-7-yl]-2-[(triphenylmethoxy)methyl]-, 1,1-dimethylethyl ester, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 577978-29-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-5-[4-methoxy-5-[(phenylmethoxy)methyl]-5H-pyrrolo[3,2-d]pyrimidin-7-yl]-4-(2-propenyloxy)-2-[(triphenylmethoxy)methyl]-, 1,1-dimethylethyl ester, (2R,3R,4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 577978-30-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-2-[4-methoxy-5-[(phenylmethoxy)methyl]-5H-pyrrolo[3,2-d]pyrimidin-7-yl]-4-(2-propenyloxy)-5-[(triphenylmethoxy)methyl]-, 1,1-dimethylethyl ester, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 577978-31-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-hydroxy-4-[(4-methoxyphenyl)methoxy]-2-[4-methoxy-5-[(phenylmethoxy)methyl]-5H-pyrrolo[3,2-d]pyrimidin-7-yl]-5-[(triphenylmethoxy)methyl]-, 1,1-dimethylethyl ester, (2S,3S,4R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:376641 CAPLUS
DOCUMENT NUMBER: 138:385438
TITLE: Preparation of pyridazinylmethanoylphenylhydrazonomalonitriles as phosphodiesterase IV inhibitors.
INVENTOR(S): Eggenweiler, Hans-Michael; Wolf, Michael; Beier, Norbert; Schelling, Pierre; Ehring, Thomas
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039548	A1	20030515	WO 2002-EP11351	20021010

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2001-125455 A 20011105
OTHER SOURCE(S): MARPAT 138:385438
GI



I

AB Title compds. [I; R1, R2 = H, OH, OR5, SR5, SOR5, SO2R5, X; R1R2 = OCH2O, OCH2CH2O; R3, R31 = H, R5, OH, OR5, NH2, NHR5, NHCOR5, X, CO2H, CO2R5, CONH2, etc.; R4 = cyano, tetrazolyl; R5 = (fluoro-substituted) A, cycloalkyl, (CH2)nAr; A = (fluoro- and/or chloro-substituted) alkyl, alkenyl; Ar = Ph; n = 0-2; X = F, Cl, Br, iodo], were prepared Thus, [3-(3,4-diethoxyphenyl)-5,6-dihydro-4H-pyridazine-1-yl]-(3-aminophenyl)methanone (preparation given) was stirred with NaNO2 in aqueous HCl for 1 h at -2° to 0°; malononitrile in H2O was added followed by stirring for 2 h to give a residue which was treated with KOH in MeOH to give 2-[[3-[1-[3-(3,4-diethoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]methanoyl]phenyl]hydrazono]malononitrile K salt. I were said to give a marked reduction of **T cell proliferation**. I are claimed for treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases, AIDS, etc.

IT **83799-24-0**, Fexofenadine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of pyridazinylmethanoylphenylhydrazonomalonitriles as phosphodiesterase IV inhibitors)

RN 83799-24-0 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:824108 CAPLUS
DOCUMENT NUMBER: 134:536
TITLE: Chemical compounds having potassium channel blocking activity for the treatment of immune dysfunction
INVENTOR(S): Jensen, Bo Skaaning; Olesen, Soren Peter; Christophersen, Palle
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069439	A1	20001123	WO 2000-DK253	20000512
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1181016	A1	20020227	EP 2000-926719	20000512
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002065247	A1	20020530	US 2001-986725	20011109
PRIORITY APPLN. INFO.:			DK 1999-659 A	19990512
			WO 2000-DK253 W	20000512

OTHER SOURCE(S): MARPAT 134:536

AB The present invention relates to chemical compds. having inhibitory activity on an intermediate conductance Ca2+-activated potassium channel (IKCa) in T- and B-lymphocytes, and the use of such compds. for the treatment or alleviation of diseases or conditions related to immune dysfunction. The invention also provides a pharmaceutical compns. comprising an effective amount of a IKCa blocker for treatment or alleviation of diseases or conditions related to immune dysfunction. For example, **T cell proliferation** was assays 6 days after cells were stimulated in culture with antigen in the presence of cyclosporin A, or cyclosporin A and clotrimazole, resp. Clotrimazole (10 μM) was added 30 min prior to the addition of antigen. The cyclosporin A-mediated inhibition of **T cell proliferation** is shifted leftwards by 10 μM clotrimazole, from a 50% inhibition of proliferation at approx. 25 nM cyclosporin A to half-maximal inhibition at 2.5 nM cyclosporin A.

IT **6922-89-0**, (4-Chlorophenyl-diphenyl)-carbinol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing potassium channel blockers and immunosuppressants for treatment of immune dysfunction)

RN 6922-89-0 CAPLUS
CN Benzenemethanol, 4-chloro-α,α-diphenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:344846 CAPLUS

DOCUMENT NUMBER: 131:13987
TITLE: Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
INVENTOR(S): Olesen, Soren-Peter; Jensen, Bo Skaaning; Jorgensen, Tino Dyhring; Strobaek, Dorte; Christophersen, Palle; Odum, Niels
PATENT ASSIGNEE(S): Neurosearch A/S, Den.
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925347	A2	19990527	WO 1998-DK490	19981113
WO 9925347	A3	19990729		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9912245	A1	19990607	AU 1999-12245	19981113
EP 1052990	A2	20001122	EP 1998-955387	19981113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 2002119989	A1	20020829	US 2000-550645	20000414
US 6545028	B2	20030408		

PRIORITY APPLN. INFO.: DK 1997-1298 A 19971114
DK 1998-386 A 19980319
WO 1998-DK490 W 19981113

OTHER SOURCE(S): MARPAT 131:13987

AB The present invention relates to chemical compds. having inhibitory activity on an intermediate conductance Ca2+-activated potassium channel (IKCa), and the use of such compds. for the treatment or alleviation of diseases or conditions relating to immune dysfunction. Moreover, the invention relates to a method of screening a chemical compound for inhibitory activity on an intermediate conductance Ca2+ activated potassium channel (IKCa). E.g., clotrimazole and nitrendipine inhibited antigen-induced **T-cell proliferation** and thus are useful for reduction or inhibition of undesired immunoregulatory actions. From the kinetics of inhibition of Ca2+-activated potassium current, an IC50 value of 153 nM for clotrimazole was calculated

IT **66774-02-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(screening of Ca2+-activated potassium channel inhibitors for treatment of immune dysfunction)

RN 66774-02-5 CAPLUS
CN Benzenemethanol, 2-chloro-α,α-diphenyl- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:102289 CAPLUS
DOCUMENT NUMBER: 122:240203
TITLE: Synthesis of immunosuppressive neoglycoproteins: bovine serum albumin coupled with 8-(hydrazinocarbonyl)octyl 4- or 6-O-α-D-mannopyranosyl-α-D-mannopyranoside
AUTHOR(S): Wada, Kaoru; Chiba, Taku; Takei, Yutaka; Ishihara, Hideko; Hayashi, Hidetoshi; Onozaki, Kikuo
CORPORATE SOURCE: Fac. Pharmaceutical Sci., Nagoya City Univ., Nagoya, 467, Japan
SOURCE: Journal of Carbohydrate Chemistry (1994), 13(7), 941-65
CODEN: JCACDM; ISSN: 0732-8303
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The title compds. were prepared by standard methods and coupled with bovine serum albumin by the acyl azide method. Antibodies against the mannose dimers were generated and an ELISA was established to measure small amts. of mannose dimers coupled to proteins. The title compds. appeared to inhibit the antigen-specific human **T cell proliferation** over 100-fold more efficiently than free mannose dimers.

IT **162129-96-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of immunosuppressive bovine serum albumin-coupled hydrazinocarbonyloctyl mannopyranosylmannopyranoside)

RN 162129-96-6 CAPLUS
CN Nonanoic acid, 9-[[2,3,4-tri-O-acetyl-6-O-(triphenylmethyl)-α-D-mannopyranosyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).